Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study ; volume:11 ; number:1 ; day:11 ; month:6 ; year:2018 ; pages:1-4 ; date:12.2018
Journal of hematology & oncology ; 11, Heft 1 (11.6.2018), 1-4, 12.2018
- Creator
-
Reda, Gianluigi
- Contributor
-
Fattizzo, Bruno
Cassin, Ramona
Mattiello, Veronica
Tonella, Tatiana
Giannarelli, Diana
Massari, Ferdinando
Cortelezzi, Agostino
SpringerLink (Online service)
- DOI
-
10.1186/s13045-018-0626-0
- URN
-
urn:nbn:de:101:1-2018082023000763876367
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Reda, Gianluigi
- Fattizzo, Bruno
- Cassin, Ramona
- Mattiello, Veronica
- Tonella, Tatiana
- Giannarelli, Diana
- Massari, Ferdinando
- Cortelezzi, Agostino
- SpringerLink (Online service)
Other Objects (12)
Ibrutinib dose modifications in the management of CLL
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)
Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL
Biochemical predictors of postoperative atrial fibrillation following cardiac surgery
Atrial fibrillation
Left atrial volume index and interleukin-6 as predictors for postoperative atrial fibrillation
Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
CLL-Erstlinientherapie mit Ibrutinib : 30 Fragen und Antworten für Ärzt*innen
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Ibrutinib dose modifications in the management of CLL
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)
Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL
Biochemical predictors of postoperative atrial fibrillation following cardiac surgery
Atrial fibrillation
Left atrial volume index and interleukin-6 as predictors for postoperative atrial fibrillation
Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
CLL-Erstlinientherapie mit Ibrutinib : 30 Fragen und Antworten für Ärzt*innen
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Ibrutinib dose modifications in the management of CLL
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)
Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL
Biochemical predictors of postoperative atrial fibrillation following cardiac surgery
Atrial fibrillation
Left atrial volume index and interleukin-6 as predictors for postoperative atrial fibrillation
Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
CLL-Erstlinientherapie mit Ibrutinib : 30 Fragen und Antworten für Ärzt*innen
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL